OCTN2 is also present in the blood brain barrier [29] and l-carnitine-conjugated poly(lactic-co-glycolytic acid) nanoparticles were shown to undergo transcytosis through this barrier and to be taken-up by glioma cells through OCTN2, which could improve the anti-glioma treatment [108]. This evidence concerns the gene SLC22A5 and central nervous system cancer.